Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits

Trial Profile

Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 3 Nov 2018 to 10 Nov 2019.
    • 27 Feb 2018 Planned primary completion date changed from 3 Nov 2018 to 10 Nov 2019.
    • 13 Feb 2017 Planned primary completion date changed from 1 Nov 2017 to 3 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top